What is Deciphex?
Deciphex is at the forefront of revolutionizing clinical and research pathology with its advanced digital pathology software and services. The company aims to enhance pathologist efficiency by integrating artificial intelligence with digital pathology, addressing the critical supply and demand challenges in the field. By developing cleverly positioned solutions, Deciphex is poised to lead the transformation of pathology services, offering a scalable and effective approach to modern diagnostic needs.
How much funding has Deciphex raised?
Deciphex has raised a total of $67.1M across 6 funding rounds:
Other Financing Round
$2.3M
Series A
$6.2M
Series B
$11.5M
Other Financing Round
$4.2M
Debt
$10.6M
Series C
$32.3M
Other Financing Round (2019): $2.3M, investors not publicly disclosed
Series A (2020): $6.2M led by Act Venture Capital Ltd, Irrus Investments, Enterprise Ireland, GI Partners of Illinois LLC, Halo Business Angel Network, and NextSteps Capital LLC
Series B (2022): $11.5M supported by Act Venture Capital and Charles River Laboratories India Private
Other Financing Round (2023): $4.2M featuring Seroba Life Sciences Management
Debt (2023): $10.6M backed by Claret Capital Partners
Series C (2025): $32.3M with participation from NextSteps Capital, Charles River, Molten Ventures, ACT Venture Capital, hban.cn, Irrus Investments, and Seroba
Key Investors in Deciphex
Claret Capital Partners
Claret Capital Partners is a Leader in European Growth Lending, providing growth capital to innovative growth stage businesses. Since 2013 Claret has backed over 140 European SMEs from a wide range of geographies across Europe. The Claret team has been active in the technology financing markets for over 20 years and provides debt solutions to help entrepreneurs and private equity investors grow their companies while minimising dilution.
Act Venture Capital
ACT Venture Capital makes venture capital investments in entrepreneurial and innovative companies. Based in Ireland, they have been investing in Ireland & the UK for over 15 years, directly investing over 350m in ambitious companies that share their goal. They partner with teams and individuals who can make an impact in their markets, with innovative products and business models, and build significant long-term value.
Seroba
Seroba is a European life sciences venture capital firm based in Dublin and Paris, investing its fourth Fund. They focus on value creation through backing cutting-edge biotech and medtech innovation that will transform the treatment of unmet medical needs. Their team has deep industry and operational experience and an extensive global network.
What's next for Deciphex?
The substantial enterprise-level funding and recent strategic investment indicate Deciphex is in a significant growth phase, likely focused on scaling its operations, expanding its technological capabilities, and broadening its market reach. This capital infusion will empower the company to further develop its AI-driven pathology platform, enhance its service offerings, and solidify its position as a leader in the digital pathology revolution. Future strategic initiatives may include deeper integration with healthcare systems and research institutions, as well as potential international expansion to meet the growing global demand for efficient pathology solutions.
See full Deciphex company page
